Alyeska Investment Group’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-62,797
Closed -$1.61M 572
2024
Q1
$1.61M Sell
62,797
-282,828
-82% -$7.25M 0.01% 390
2023
Q4
$9.54M Buy
+345,625
New +$21.1M 0.06% 265
2020
Q3
Sell
-21,162
Closed -$16.7M 471
2020
Q2
$16.7M Buy
+21,162
New +$16M 0.25% 135
2019
Q2
Sell
-149
Closed -$304K 444
2019
Q1
$304K Sell
149
-2,936
-95% -$5.17M ﹤0.01% 359
2018
Q4
$3.96M Buy
+3,085
New +$4.73M 0.06% 243
2018
Q3
Sell
-5,071
Closed -$10.3M 415
2018
Q2
$10.3M Buy
+5,071
New +$11.6M 0.09% 199
2018
Q1
Sell
-1,390
Closed -$3.21M 456
2017
Q4
$3.21M Buy
+1,390
New +$2.82M 0.03% 290
2017
Q2
Sell
-21,539
Closed -$25.4M 457
2017
Q1
$25.4M Sell
21,539
-1,320
-6% -$1.35M 0.21% 159
2016
Q4
$18.3M Buy
+22,859
New +$18.2M 0.15% 214
2015
Q4
Sell
-3,474
Closed -$3.85M 385
2015
Q3
$3.85M Buy
+3,474
New +$6.33M 0.05% 277
2014
Q4
Sell
-6,767
Closed -$3.15M 489
2014
Q3
$3.15M Buy
+6,767
New +$3.12M 0.06% 262
2014
Q1
Sell
-1,787
Closed -$486K 329
2013
Q4
$486K Sell
1,787
-1,301
-42% -$364K 0.02% 284
2013
Q3
$1.08M Buy
3,088
+772
+33% +$287K 0.04% 257
2013
Q2
$749K Buy
+2,316
New +$764K 0.04% 252

Other funds holding BLUE

Alyeska Investment Group's BLUE Position: Q2 2024 in Review

Alyeska Investment Group sold out of bluebird bio (BLUE) in Q2 2024, closing a stake of 62,797 shares — an estimated $1.61M sold.

Alyeska Investment Group first reported a position in BLUE in Q2 2013 and held it in 14 quarters. The position peaked at $25.4M in Q1 2017. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2024.

  • Alyeska Investment Group reported no remaining bluebird bio position as of Q2 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 62,797 bluebird bio shares in Q2 2024, an estimated $1.61M.
  • Alyeska Investment Group first reported a position in bluebird bio in Q2 2013 and held it in 14 quarters.
  • Alyeska Investment Group's bluebird bio position peaked at $25.4M in Q1 2017.
  • 150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2024.

Based on Alyeska Investment Group's 13F filing for Q2 2024, filed 14 Aug 2024.